Our Pipeline

VB-201

Our lead compound, VB-201, has significant potential to treat inflammation in chronic diseases such as psoriasis, inflammatory bowel disease, multiple sclerosis, rheumatoid arthritis and atherosclerosis.

VB-201 acts as a counterbalance to the pro-inflammatory immune system activity that occurs in chronic disorders without significantly affecting system-wide immune factors, and is well-positioned to work as a monotherapy or as part of a combination of therapies. The compound is a first-in-class, orally administered immune-response modifier and is expected to reduce inflammation in a broad range of conditions.

• Preclinical Insights – In extensive preclinical studies, VB-201 demonstrated efficacy in multiple immune-inflammatory conditions, including psoriasis. VB-201 showed a unique disease-modifying mechanism for attenuating cell-mediated, pro-inflammatory processes. The favorable safety and efficacy profile observed in preclinical model paved the way for a U.S. IND and Phase 1 clinical trials.

• Phase 1 Clinical Trials Complete – VB-201 successfully completed four Phase 1 clinical trials involving 120 healthy volunteers under a U.S. IND. This includes single and multiple-dose studies in which safety and tolerability were similar to placebo.

• Phase 2 Clinical Trials Underway – We have initiated a Phase 2 efficacy and safety study evaluating VB-201 for the treatment of patients with psoriasis. The Phase 2 double-blind, randomized, dose-ranging, placebo-controlled study will enroll approximately 180 patients with moderate to severe psoriasis. Patients will receive VB-201 or placebo once-daily for 12 weeks. The primary endpoint in the study is improvement in the Psoriasis Area and Severity Index (PASI 75) at week 12. The study will be conducted at multiple centers in the United States, Germany and Israel.

Detailed information on the clinical trial can be found at www.clinicaltrials.gov.